Navigation Links
Martek Signs Multi-Year Infant Formula License and Supply Agreement with Alter Farmacia
Date:10/5/2007

COLUMBIA, Md., Oct. 5 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation announced today that it has entered into a multi-year license and supply agreement with Alter Farmacia, S.A. for the inclusion of Martek's arachidonic acid (ARA) oil in Alter's infant formula products. Under the terms of the agreement, Alter Farmacia will purchase Martek's ARA for all of its infant formula products that contain ARA sold in Spain and Portugal.

Headquartered in Spain, Alter Farmacia is part of the Alter Group and markets baby foods, infant formula, and cosmetics.

Naturally present in human breast milk, ARA is an essential fatty acid important to infant development and growth. When used in combination with DHA, clinical studies have demonstrated numerous benefits for infants receiving ARA supplemented formula. Martek's ARA is the only ARA currently used in U.S. infant formulas, and is present in more than 90 percent of infant formula sold in the U.S.

"This product launch is another step towards Martek's goal of further expanding our infant formula market outside of the U.S., where we are already in more than 90 percent of infant formulas sold," said Steve Dubin, CEO of Martek. "It's satisfying to know that with every new license agreement, more and more infants around the world will benefit from Martek's products."

Martek Biosciences Corporation (Nasdaq: MATK) is a leader in the innovation and development of DHA omega-3 products that promote health and wellness through every stage of life. The company produces life'sDHA(TM), a sustainable and vegetarian source of the omega-3 fatty acid DHA (docosahexaenoic acid), for use in foods, beverages, infant formula, and supplements. The company also produces life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, from a sustainable, vegetarian source, for use in infant formula. For more information on Martek Biosciences Corporation, visit http://www.martek.com.

Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2006 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.

CONTACT

Cassie France-Kelly

Public Relations

(443) 542-2116

cfrancekelly@martek.com

Kyle Stults

Investor Relations

(410) 740-0081

investors@martek.com


'/>"/>
SOURCE Martek Biosciences Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Filtration treatment assigns more live kidney donation
2. Depressed women show signs of earlier onset of Perimenopause
3. More signs to an approaching migraine attack
4. An Indian Bride with signs of SARS
5. Recognize Heart Attack Signs
6. Parents Should Look For Signs Of Children Becoming Overweight
7. Early Warning Signs Of Heart Disease
8. Warning Signs On Powered Baby Milk
9. Genetical Screening Can Detect Early Signs Of Multiple Sclerosis
10. Diagnosis of Alzheimers years before clinical signs emerge
11. President and Founder of National Obesity Forum Resigns
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... ... November 30, 2016 , ... The Fertility Centers ... as a Cigna Infertility Center of Excellence. The Cigna Center of Excellence recognizes ... an honor to be designated a Cigna Infertility Center of Excellence," said Fertility ...
(Date:11/30/2016)... , ... November 30, 2016 , ... "I hate when ... arm while brushing my teeth," said an inventor from Bridgewater, N.J. "I thought that ... develop this handy device." , He developed the patent-pending DEFLECTOR to prevent saliva and ...
(Date:11/30/2016)... FL (PRWEB) , ... November 30, 2016 , ... ... disorder and mental health treatment has announced the opening of a new eating ... partial hospitalization and intensive outpatient treatment for adults and adolescents, both males and ...
(Date:11/30/2016)... ... November 30, 2016 , ... In recent policy debates, increasing ... public policymakers and system stakeholders in many states. To help them understand this ... Index for Workers’ Compensation, Eighth Edition (MPI-WC) . , “If you are a ...
(Date:11/30/2016)... ... 30, 2016 , ... The Clinical Data Interchange Standards Consortium ... Guidance goes into effect next month. Sponsors whose studies start after December 17, ... Catalog. The current FDA Data Standards Catalog specifies the use of CDISC standards: ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2, 2016  UCB is pleased to announce that 12 scientific ... 70 th American Epilepsy Society (AES) Annual Meeting, which ... , USA. 1-12 Data being ... of VIMPAT ® (lacosamide) CV and BRIVIACT ® ... the current state of the union of epilepsy care and ...
(Date:12/2/2016)... , December 2, 2016 The iShares ... past losses following Trump,s victory early in November. Less ... fund managers are now predicting an uptick in M&A ... equities to see how they have fared at the ... ), Amicus Therapeutics Inc. (NASDAQ: FOLD ), ...
(Date:11/30/2016)... -- Research and Markets has announced the addition of ... report to their offering. ... Detachable coil embolization is a minimally ... detachable coil embolization treatment of cerebral aneurysms is less invasive and requires ... in the wall of an artery in the brain. This area bulges ...
Breaking Medicine Technology: